Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.
Jan B. Vermorken(University of Antwerp), Paul M. Clément(Universitair Ziekenhuis Leuven), Tim H. Brümmendorf(Heidelberg University), Jean‐Pierre Delord, Éva Remenár(National Institute of Oncology), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Thomas Gauler, Juergen Krauss(National Center for Tumor Diseases), Philippe Schafhausen(University Medical Center Hamburg-Eppendorf), Ulrich Keilholz(German Cancer Research Center), Guillaume de La Bourdonnaye(Merck Serono S.A. (Switzerland)), Ullrich Bethe(European Organisation for Research and Treatment of Cancer), József Erfán, L. Iglesias(Research Institute Hospital 12 de Octubre), Frédéric Peyrade(Centre Hospitalier Universitaire de Nantes)
Cited by 7
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
|The Lancet|2008|644
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|621